FDA Releases Initial Guidelines for Cannabis-Derived Drugs
- Agency publishes draft and opens floor to industry comments
- Only one CBD-derived drug has been approved so far by the FDA
This article is for subscribers only.
The Food and Drug Administration released a draft of rules that companies should follow to develop cannabis-derived drugs -- a new category that has exploded with few federal laws to govern it.
The guidelines cover drugs and treatments containing cannabis oil and other compounds found in the plant, the agency said on Tuesday. They include references for calculating weights for oral dosages and online resources related to clinical trials for cannabis-derived products.